Comparable stake leader
1Globe Capital LLC
SEC ownership of SINOVAC BIOTECH LTD
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001084201.
Disclosed value leader
Vivo Capital IX, LLC
Comparable rows
24/24
Latest evidence
17 Apr 2026
- Public ticker
- SVA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
1Globe Capital LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
24 of 24
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
1Globe Capital LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001084201
- Issuer location
- Beijing
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of SINOVAC BIOTECH LTD (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
1Globe Capital LLC
Disclosed value leader
Vivo Capital IX, LLC
Comparable rows
24/24
Latest evidence
17 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 32%
13D/G row: 1Globe Capital LLC
Showing 1-8 of 24 holder rows.
Quick read
1Globe Capital LLC leads the comparable SEC ownership view at 32%.
24 of 24 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 1Globe Capital LLC's linked filing trail.
Comparable ownership
Top 5
1Globe Capital LLC
32%
SAIF Partners IV L.P.
15%
Yin Weidong
8.8%
Advantech Capital L.P.
8.1%
Vivo Capital IX, LLC
6.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 24 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 1Globe Capital LLC |
13D/G
|
32%
|
—
18,515,315 shares
|
$0 | 07 Jul 2025 |
| SAIF Partners IV L.P. |
13D/G
|
15%
|
—
10,780,820 shares
|
$0 | 15 Dec 2025 |
| Yin Weidong |
3/4/5
13D/G
Chief Executive Officer, Director · Weidong Yin
|
8.8%
from 13D/G
|
$41,145,965
6,359,500 shares
|
— | 18 Mar 2026 |
| Advantech Capital L.P. |
13D/G
|
8.1%
|
—
5,851,423 shares
|
$0 | 08 Jul 2025 |
| Vivo Capital IX, LLC |
13D/G
|
6.3%
|
$293,522,587
4,539,456 shares
|
$0 | 17 Mar 2025 |
| Vivo Capital VIII, LLC |
13D/G
Vivo Capital IX, LLC
|
6.3%
|
—
4,541,764 shares
|
$0 | 11 Jul 2025 |
| Jiaqiang Li |
3/4/5
Director
|
26%
|
$119,803,345
18,515,315 shares
|
— | 17 Apr 2026 |
| Andrew Y. Yan |
3/4/5
Director
|
15%
|
$69,751,905
10,780,820 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to SINOVAC BIOTECH LTD. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Jiaqiang Li
Net 12M change
$0
Latest report
17 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jiaqiang Li | Director | $119,803,345 | Median | 17 Apr 2026 | ||
| Andrew Y. Yan | Director | $69,751,905 | Mixed | 18 Mar 2026 | ||
| Yin Weidong | Chief Executive Officer, Director | $41,145,965 | Mixed | 18 Mar 2026 | ||
| Fu Shan | Director | $38,192,410 | Mixed | 18 Mar 2026 | ||
| Nan Wang | Chief Financial Officer | $2,296,850 | Mixed | 18 Mar 2026 | ||
| Qiang (nmn) Gao | Chief Operation Officer | $1,488,100 | Mixed | 18 Mar 2026 | ||
| Jing (nmn) Li | VP, Quality and Production | $1,471,925 | Mixed | 18 Mar 2026 | ||
| Guang (helen) Yang | Chief Business Officer | $1,118,663 | Mixed | 18 Mar 2026 | ||
| Yuk Lam Lo | Director | $582,300 | Mixed | 18 Mar 2026 | ||
| Simon Anderson | Director | $452,900 | Mixed | 18 Mar 2026 | ||
| Yu Min Qiu | Director | Mixed | 18 Mar 2026 | |||
| Yu (nmn) Wang | Director | Mixed | 18 Mar 2026 | |||
| Shuge Jiao | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for SINOVAC BIOTECH LTD
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jiaqiang Li | SVA | Common shares, par value $0.001 per share | 0 | 18,515,315 | 17 Apr 2026 | By 1Globe Capital LLC, CDH Utopia Limited and the others | ||||
| Jing (nmn) Li | SVA | Common shares, par value $0.001 per share | 0 | 227,500 | 18 Mar 2026 | Direct | ||||
| Guang (helen) Yang | SVA | Common shares, par value $0.001 per share | 0 | 172,900 | 18 Mar 2026 | Direct | ||||
| Fu Shan | SVA | Common shares, par value $0.001 per share | 0 | 5,903,000 | 18 Mar 2026 | By Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P. | ||||
| Simon Anderson | SVA | Common shares, par value $0.001 per share | 0 | 70,000 | 18 Mar 2026 | Direct | ||||
| Yin Weidong | SVA | Common shares, par value $0.001 per share | 0 | 6,359,500 | 18 Mar 2026 | Direct | ||||
| Andrew Y. Yan | SVA | Common shares, par value $0.001 per share | 0 | 10,780,820 | 18 Mar 2026 | By SAIF Partners IV L.P. | ||||
| Qiang (nmn) Gao | SVA | Common shares, par value $0.001 per share | 0 | 230,000 | 18 Mar 2026 | Direct | ||||
| Nan Wang | SVA | Common shares, par value $0.001 per share | 0 | 355,000 | 18 Mar 2026 | Direct | ||||
| Yuk Lam Lo | SVA | Common shares, par value $0.001 per share | 0 | 90,000 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.